How does concomitant ivosidenib affect triazole levels in patients with AML or MDS who receive antifungal prophylaxis?
Read our summary of a retrospective study to learn more: loom.ly/Ae_QQMU
#AMLsm #leusm #leukemia #MedicalEducation

What is the optimal induction chemotherapy regimen for younger patients with newly diagnosed acute myeloid leukemia without adverse risk cytogenetics?

👉Read our summary of results from the UK AML19 trial here: loom.ly/0HLbjSM

#leusm #AMLsm

AN INCREDIBLE END TO ONE OF THE MOST INCREDIBLE DERBY GAMES YOU WILL HAVE EVER SEEN.

Step forward, Sir Amad Diallo ♥️

Manchester United have won it in extra-time with seconds to go!!!

#EmiratesFACup

Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome Journal of Clinical Oncology Naval Daver, M.D. ascopubs.org/doi/10.1200/JC…

Post induction molecular #MRD identifies patients with #NPM1 #AML who benefit from allogeneic transplant in first remission
doi.org/10.1182/blood.…
#leusm #BMTsm #CR1 Blood Journal Mike Dennis

Another predictive model in CART for rrDLBCL. #CART24

Not unexpected but I’m sure there is more we can learn from the P1-3 development of magro- FDA Halts Clinical Studies of Magrolimab in AML, MDS targetedonc.com/view/fda-halts…

NPM1 MRD by qRT-PCR provides valuable prognostic information in patients with AML treated with venetoclax combinations. ow.ly/rPBT50QuyFh #myeloidneoplasia #clinicaltrialsandobservations

Fludarabine, Cytarabine, GCS-F and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Great to see the excellent results from AML19 now published in Journal of Clinical Oncology -
ascopubs.org/doi/full/10.12…

As a current NHS doctor, it makes me sad and angry to see former doctors involved in political action which I believe to be unethical and unforgivable given the harm being done to the whole NHS by years of conservative government

REVIEW 2023-Pioneering research in Manchester showed dramatic results for treating children with high-risk leukaemia who previously had no hope of recovery after all other treatment options had failed. aboutmanchester.co.uk/i-knew-this-tr…

📢 NEWS: Belumosudil has been approved by NICE for chronic GvHD

We’ve been calling for better access to GvHD treatments for a long time, so we’re delighted that a new treatment option will now be available to patients across the UK who have not responded to other therapies.

Catching up on last weekend #ASH23 great to see ⁦Jad Othman⁩ slides from AML17/19 study ⁦Science and Innovation at Cancer Research UK⁩ funded ⁦Cardiff University⁩ sponsored selected as ‘Best of ASH’ 👏🏼👏🏼👏🏼

Now, which clinical investigator is going to step up and dedicate themselves to doing the confirmatory prospective RCT? Biomarker available. A chance to change clinical practice.

Congrats to Jad Othman for having his abstract highlighted in the Best of ASH session!
Beautiful data showing the value of post induction NPM1 MRD in guiding the always tough decision of CR1 allograft
#ASH23

Great meetings with multiple global haem-onc pharma companies who recognise opportunity for trials acceleration offered by Accelerating Clinical Trials and its TAP and IMPACT trial networks. Confirms vital importance of trial innovation and benefits for UK patients as highlighted by James O'Shaughnessy

#Manchester myeloid team!
#MDSsm #CMMLsm #leusm #ASH23
Dan Wiseman Kiran Batta naseer basma ASH Division of Cancer Sciences CRUK Manchester Institute The Christie NHS

✅✅✅Amazing presentation from Yu-Hung Wang on MF risk stratification at the #MPNsm session at #ASH23 - congrats! 👏🏻 The Christie NHS

This was an intriguing and beautifully presented abstract: AML keeps us on our toes with clonal complexity and mechanisms of relapse following ven exposure in elderly NPM1 AML. Great work!